Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
2015 · BMC Medical Genomics · 547 citations
https://doi.org/10.1186/s12920-015-0129-6
B
Brett Wallden
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
43
Papers
1.4K
Citations
9
h-index
9
i10-index
Brett Wallden is an academic researcher from Foundation Medicine (United States). The author has contributed to research in topics: Breast Cancer Treatment Studies & BRCA gene mutations in cancer & Breast Lesions and Carcinomas. The author has an h-index of 9, co-authored 37 publications.
Papers by this author
worksAnalytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
2014 · BMC Cancer · 303 citations
https://doi.org/10.1186/1471-2407-14-177
Additional file 6: of Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
2018 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.6651377
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
2014 · Open MIND · 0 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat